Journal
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
Volume 10, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2045125320905752
Keywords
bipolar depression; bipolar disorder; cariprazine; mania; mixed features
Categories
Ask authors/readers for more resources
Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as 'atypical' second generation antipsychotics. Originally approved for acute and maintenance treatment of schizophrenia as well as for acute mania and mixed mania/depression, cariprazine has now been approved for bipolar I depression. Additionally, post hoc analyses of bipolar I depressed subjects show that both those with and those without concurrent manic features were improved following treatment with cariprazine. Maintenance studies are in progress in bipolar disorder, as are studies to augment antidepressants in unipolar major depressive episodes insufficiently responsive to treatment. Here, we review specifically the efficacy and safety data of cariprazine in bipolar I disorder and discuss the hypothesized mechanism of action of cariprazine and how it could theoretically be linked to caprazine's broad therapeutic actions across the mood disorder spectrum.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available